Short-term interferon therapy for chronic hepatitis C patients with low viral load

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 968-972

  Sato, Yoshihisa ^a   Tokuue, Hideki ^a   Kawamura, Naohiro ^a   Nezu Yajima, Saeko ^a   Nakijima, Hiroshi ^a   Ishida, Hitoshi ^a   Takahashi, Shin Ichi ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Low viral load; Short term interferon therapy

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 3042513712     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Freza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, The Triveneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-706.
2. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JR: Lack of benefit of escalating dosage of interferon alfa in patients with hepatitis C. Gastroenterology 1995; 109:156-165.
3. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saito S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H: Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-1094.
4. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Breton VL, Milotova V, Benhamou JP, Erlinger S: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22:1050-1056.
5. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, Collaborative study group: Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122:161-168.
6. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primary on hepatitis C virus RNA level. Hepatology 1995; 22:1121-1130.
7. Lindsey KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JYN, Maertens G, Gogate J, Sanghvi B, Albrecht J, The Hepatitis Interventional Therapy Group: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24:1034-1040.
8. Shiratori Y, Kato N, Yokosuka O, Fumio I, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M, The Tokyo-Chiba Hepatitis Reseach Group: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113:558-566.
9. Poynald T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24:778-789.
10. Richard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Ola Weiland for the Swedish Study Group: Randomized, double-blind, placebo-controlled trial of interferon□-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-87.
11. Poynald T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, The International Hepatitis Interventional Therapy Group: Randomized trials of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon □2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
12. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, The Hepatitis Interventional Therapy Group: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
13. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282:103-107.
14. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-231.
15. Iino S: High dose interferon treatment in chronic hepatitis C. Gut 1993; (Suppl):s114-118.
16. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus by polymerase chain reaction with two-specific primers; implication to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
17. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74:2391.
18. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, Yokosuka O, Suzuki H: New Inuyama classification; new criteria for histological assessment of chronic hepatitis. International Hepatology Communications 1996; 6:112-119.
19. Poynald T, McHutchison J, Goodman Z, Ling MH, Albrecht J, Algovirc Project Group: Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31:211-218.
20. Camma C, Giunta M, Chemello L, Alberti A, Toyota H, Trepo C, Marcellin P, Zahn F, Schalm S, Craxi A, The European Concerted Action on Viral Hepatitis: Chronic hepatitis C: Interderon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999; 30:801-807.